Stockreport

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease ...

BioLineRx Ltd. - American Depositary Shares  (BLRX) 
Last biolinerx ltd. - american depositary shares earnings: 5/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.biolinerx.com
PDF - Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies fo [Read more]